The efficacy of chemotherapy in the advanced NSCLC patients who failed with the treatment of EGFR-TKI

被引：0
|
作者：
Zhou, S. [1 ]
Ren, S. [1 ]
Zhang, L. [1 ]
Sun, H. [1 ]
Zhou, C. [1 ]
机构：
[1] Tongji Univ, Affliated Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19078
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy
    Zhou, Shujie
    Ren, Fei
    Meng, Xiangjiao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [12] Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance
    Li, Yujing
    Jiang, Haohua
    Qian, Fangfei
    Chen, Ya
    Zhou, Wensheng
    Zhang, Yanwei
    Lu, Jun
    Lou, Yuqing
    Han, Baohui
    Zhang, Wei
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [13] Time to EGFR-TKI Treatment for Patients with Advanced NSCLC and EGFR Activating Mutation in a Tertiary Cancer Center
    Le Guevelou, Jennifer
    Dugue, Audrey
    Richard, Nicolas
    Dubos, Catherine
    Do, Pascal
    Danhier, Serge
    Lerouge, Delphine
    Bonneau, Jessica
    Blanc, Cecile
    Gervais, Radj
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1229 - S1229
  • [14] The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI
    Lu, S.
    Wang, Q.
    Zhang, G.
    Dong, X.
    Yang, C.
    Song, Y.
    Chang, G.
    Lu, Y.
    Pan, H.
    Chiu, C.
    Wang, Z.
    Feng, J.
    Zhou, J.
    Xu, X.
    Guo, R.
    Chen, J.
    Yang, H.
    Chen, Y.
    Yu, Z.
    Shiah, H.
    Wang, C.
    Yang, N.
    Fang, J.
    Wang, P.
    Wang, K.
    Hu, Y.
    He, J.
    Wang, Z.
    Shi, J.
    Chen, S.
    Cheng, Y.
    Su, W.
    Hsia, T.
    Cui, J.
    Sun, Y.
    Yang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S208 - S209
  • [15] RETREATMENT WITH ERLOTINIB FOR PATIENTS WITH NSCLC WHO BENEFITTED FROM PREVIOUS EGFR-TKI TREATMENT.
    Crombag, Laurence M. M.
    Becker, Annemarie
    Van Wijk, Atie W.
    Postmus, Pieter E.
    Smit, Egbert F.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S664 - S665
  • [16] Dynamics of Soluble PD-1 during Treatment with EGFR-TKI in Advanced NSCLC Patients
    Sorensen, Steffen F.
    Demuth, Christina
    Sorensen, Boe S.
    Meldgaard, Peter
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S602 - S602
  • [17] EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC
    da Silva, L. L.
    Matsas, S.
    Aguiar, P., Jr.
    Taveira, G. M. T.
    Barcelos, I. F.
    Lopes, G. L., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S417
  • [18] EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy
    Wang, L.
    Su, S.
    Lv, X.
    Liu, Y.
    Chen, F.
    Shao, J.
    Liu, B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S391 - S391
  • [19] The clinical utility of longitudinal measurement of mutated EGFR in plasma of advanced NSCLC patients during EGFR-TKI treatment
    Szpechcinski, A.
    Bryl, M.
    Wojda, E.
    Czyzewicz, G.
    Swiniuch, D.
    Szwiec, M.
    Ramlau, R.
    Sliwinski, P.
    Barinow-Wojewodzki, A.
    Chorostowska-Wynimko, J.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [20] HOW TO MAKE THE CHOICE IN THE REUSE OF EGFR-TKI FOR ADVANCED NSCLC PATIENTS WHO BENEFITED FROM PRIOR GEFITINIB THERAPY: THE ORIGINAL DRUG OR SWITCHING TO A SECOND EGFR-TKI?
    Tang, Chuanhao
    Guo, Wanfeng
    Li, Jianjie
    Wang, Weixia
    Liu, Xiaoqing
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S888 - S889
12345